MetaCap

Aclaris Therapeutics (ACRS) vs Immix Biopharma (IMMX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immix Biopharma (IMMX) has outperformed Aclaris Therapeutics (ACRS) over the past year, gaining 60.7% versus a gain of 37.1%. Immix Biopharma is the larger company by market cap ($583.3 million vs $545.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%IMMX+60.74%
+246%+113%-20%
Nov 21, 20251 yearNov 20, 2026
ACRS-75.39%IMMX+74.00%
+266%+77%-111%
Dec 13, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus IMMX key metrics
MetricACRSIMMX
Share price$3.44$6.96
Market cap$545.63M$583.33M
1-day change-1.71%-1.14%
YTD return+14.29%+33.08%
1-year return+37.05%+60.74%
5-year return-72.74%—
EPS (TTM)$-0.59$-0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M—
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-29.40M
Gross margin73.28%—
Operating margin-975.91%—
Net margin-829.58%—
52-week high$6.60$15.10
52-week low$2.46$3.78
Distance from 52-week high-47.88%-53.91%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+243.82%
Average volume3.07M1.45M
Shares outstanding158.61M83.81M
Employees6921
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMX has outperformed ACRS by 23.7 percentage points over the past year.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Immix Biopharma

IMMX stock →

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

ACRS vs IMMX FAQ

Which is bigger, Aclaris Therapeutics or Immix Biopharma?

Immix Biopharma (IMMX) is larger, with a market capitalization of $583.33M compared with $545.63M for Aclaris Therapeutics (ACRS).

Which stock has performed better over the past year, ACRS or IMMX?

IMMX returned +60.74% over the past 12 months, compared with +37.05% for ACRS (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Immix Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons